Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireProductiveAssets.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | For the six months ended June 30, 2026 | For the six months ended June 30, 2025 |
|---|---|---|
| Changes in deferred revenue | (1,190) | (6,008) |
| Net cash used in operating activities | (69,818) | (74,139) |
| Investing activities: | ||
| Purchase of property, plant and equipment, including internal use software | (118) | (104) |
| Maturities of marketable securities | 97,500 | 37,163 |
| Purchases of marketable securities | (113,653) | (193,340) |
| Net cash used in investing activities | (16,271) | (156,281) |
| Financing activities: |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's capex?
- NewAmsterdam Pharma Company (NAMS) reported capex of $80K in Q2 2026.
- How has NewAmsterdam Pharma Company's capex changed year-over-year?
- NewAmsterdam Pharma Company's capex decreased by 9.1% year-over-year, from $88K to $80K.
- What is the long-term trend for NewAmsterdam Pharma Company's capex?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's capex has grown at a 78.9% compound annual growth rate (CAGR), from $24K to $246K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about NewAmsterdam Pharma Company's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude